公开(公告)号：WO2022096470A1

公开(公告)日：2022-05-12

申请号：PCT/EP2021/080423

申请日：2021-11-02

Applicant: RANDOX LABORATORIES LTD

Inventor： DUNLOP, Marshall ,  SCHON, Shirley ,  LAMONT, John ,  FITZGERALD, Peter

IPC: C07K16/28

Abstract: The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease. Specifically, the present invention relates to therapeutic antibodies, or antigen-binding portions thereof, that target the programmed death-ligand 1 polypeptide. The present invention also relates to pharmaceutical compositions comprising said therapeutic antibody, or antigen-binding portions thereof.

公开(公告)号：WO2006030238A1

公开(公告)日：2006-03-23

申请号：PCT/GB2005/003601

申请日：2005-09-19

Applicant: RANDOX LABORATORIES LTD. ,  FITZGERALD, Peter ,  LAMONT, John ,  DUNLOP, Marshall ,  SCHON, Shirley

Inventor： FITZGERALD, Peter ,  LAMONT, John ,  DUNLOP, Marshall ,  SCHON, Shirley

IPC: C12N15/10

CPC classification number: C12N15/1093 ,  C07K16/005 ,  C07K16/18 ,  C07K2317/622

Abstract: The invention relates to a composition comprising a plurality of antibody fragments, each comprising a framework region having a murine VH14 heavy chain and a murine VK2 light chain, or homologues thereof, each antibody fragment further comprising at least one different CDR.

Abstract translation: 本发明涉及包含多个抗体片段的组合物，每个抗体片段包含具有鼠VH14重链和鼠VK2轻链的框架区或其同源物，每个抗体片段还包含至少一个不同的CDR。